Thrombotic Disorders Resource Center

ThromboSite^SM is focused to health care professionals with an interest in issues related to the pathophysiology, pharmacology, and clinical aspects of thrombosis, thrombotic disorders, and hemostasis.

Here you will find information about subscribing to the THROMBO-SITE e-mail discussion forum and how to join the online discussion. You will also find archives of past discussions, as well as articles from HIT News (reviews of literature relating to Heparin-induced Thrombocytopenia), HIT Cases (interactive case studies related to Heparin-induced Thrombocytopenia), ThromboSite Newsletter (highlights from medical meetings and other news), and other news and background information related to thrombosis, thrombotic disorders, and hemostasis.

• ThromboSite Newsletter - Recent Advancements in the Management of Heparin-Induced Thrombocytopenia.

  

• THROMBO-SITE E-mail Discussion Forum - The Thrombolytic (Vascular) Biology Discussion List (THROMBO-SITE) is a unique forum for the scientific discussion of topics related to the pathophysiology, pharmacology, and clinical aspects of thrombosis, thrombotic disorders, and hemostasis.

• Pathophysiology of Heparin-Associated Thrombocytopenia Type II

• News

• Meeting Highlights

• Case Studies

• Drugs Used to Treat Thrombotic Disorders

• ThromboGlossary

DRUGinfoline

• Aggrenox: An Anticlotting Drug for Prevention of Recurrent Stroke - Jan 2000
• Pletal for the Treatment of Intermittent Claudication - Jun 99

HIT News

• A Practical Assay for the Diagnosis of HIT? - Feb 98
• A Rare Case of Dermal Necrosis Associated with LMWH - Feb 98
• Adverse Effects of Low Molecular Weight Heparin(oid)s - Feb 98
• Anticoagulation with Argatroban During Coronary Angioplasty - Aug 98
• Aggressive Screening and Management of HIT Improves Patient Outcomes - Aug 98
• Clinical Risk Factors Associated with the Development of Thrombosis in Patients with HIT - Apr 98
• Diagnosis of HIT and Treatment Options - Aug 98
• Epitope Recognition of HITT Antibodies - Aug 98
• Heparin-Induced Thrombocytopenia: A Review - Aug 98
• Heparin-Induced Thrombocytopenia After Total Knee Arthroplasty - Apr 98
• HIPA Versus PF4 ELISA for Detecting Heparin-Induced Thrombocytopenia - Apr 98
• Is Inhibition of Tissue Factor an Option for the Prevention of Thrombotic Complications? - Apr 98
• Still No "Gold Standard" Assay for the Diagnosis of HIT - Feb 98
• Use of Recombinant Hirudin in the Management of Heparin-Induced Thrombocytopenia (HIT) - Feb 98
• What is the Importance of PF4-heparin Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia (HIT)? - Feb 98
• What is the Relationship Between Venous Limb Gangrene and HIT? - Feb 98
• Which Anticoagulant Should be Used in Patients with HIT Type II? - Apr 98

CardioConsult Reviews

• Are Anticoagulants Used Often Enough in Patients with Atrial Fibrillation? - Dec 99
• Bimonthly Boosts of Aspirin Are Good for the Heart - Mar 98
• Do Sex, Age, and Clinical Diagnosis Influence Heparin Dose Requirements? - Jan 98
• How Do Different Thrombolytic Agents Affect Platelet Function? - Jan 00
• Is Clopidogrel an Acceptable Alternative to Ticlopidine After Stent Placement? - Jan 00
• Is the Risk of Recurrent Venous Thromboembolism Dependent On Achieving a Therapeutic aPTT Result at 24 to 48 Hours? - Apr 98
• IV Heparin May Be of Little Use for Heart Attack in the Elderly - June 98
• Should Low Molecular Weight Heparin Be Used as an Adjunct to Thrombolytic Therapy for AMI? - Sep 98
• Tirofiban vs. Heparin: In Unstable Angina, the Winner Is Tirofiban - June 98

Med-Brief

• Clot-dissolving therapy for stroke victims - Feb 99
• FDA approval of drug for the prevention of deep vein thrombosis - Apr 98

Medical Sciences Bulletin

• Eptifibatide and Tirofiban Approved for Acute Coronary Syndromes - May/June 1998
• Plavix (clopidrogrel) for Unstable Angina and Stroke Prevention
• Lepirudin for Heparin-induced Thrombocytopenia Type II
• Oprelvekin for Prevention of Severe Thrombocytopenia
• Anagrelide for Essential Thrombocythemia
• More Clinical Data Filed with FDA to Support Novastan Submission

PNN Pharmacotherapy Line

• Aspirin with Warfarin for Prevention of MIs
• Cilostazol Approved for Intermittent Claudication - Jan 99
• Death Lower in Patients Receiving Eptifibatide vs. Heparin - Aug 98
• INR Range of 3.0-4.5 Found Unsafe for TIAs
• Tirofiban Approved by FDA
• Use of Antiplatelet Agents, Heparin Assessed
• Warning Issued: Paralysis with LMW Heparins

Miscellaneous Sources

• MD Digest: Is Clopidogrel an Effective New Antiplatelet Agent?

Return to top...

• American Society of Hematology Update (December, 1997 Meeting)
• More News from the American Society of Hematology (December, 1997 Meeting)

Return to top...

• abciximab (Reopro)
• alteplase (Activase)
• anagrelide (Agrylin)
• Ancrod
• ardeparin (Normiflo)
• argatroban (Novastan)
• cilostazol (Pletal)
• clopidrogrel (Plavix)
• dalteparin (Fragmin)
• danaparoid (Orgaran)
• eptifibatide (Integrilin)
• lepirudin (Refludan)
• oprelvekin (Neumega)
• saruplase
• ticlopidine(Ticlid)
• tirofiban (Aggrastat)

Last modified on 06/13/99 10:08:20 AM.

© 1999 Mediconsult.com Limited. All rights reserved. As seen on PharmInfoNet ()